A Review of Oral Antiretroviral Therapy for the Treatment of Chronic Hepatitis B

Hynicka, Lauren M.; Yunker, Nancy S.; Patel, Punam H

doi:10.1345/aph.1m590

Cited by 9 publications

(11 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, nucleotide(s) analogs (NA) and interferon (IFN) are commonly used to treat CHB (7). Although several kinds of NAs are available, including lamivudine, telbivudine, entecavir, emtricitabine, adefovir dipivoxil (ADV), and tenofovir (8), patients cannot stop treatment because covalently closed circular (ccc)DNA is stably incorporated into the nucleus of hepatocytes, even after treatment with an NA (6,8).…”

Section: Introductionmentioning

confidence: 99%

Factors associated with the decrease in hepatitis B surface antigen titers following interferon therapy in patients with chronic hepatitis B: Is interferon and adefovir combination therapy effective?

et al. 2017

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Factors associated with the decrease in hepatitis B surface antigen titers following interferon therapy in patients with chronic hepatitis B: Is interferon and adefovir combination therapy effective?

et al. 2017

View full text Add to dashboard Cite

“…However, its resistance rate is relatively high during its long-term application, due to low genetic barriers to resistance [2]. According to the results of the Global study, the effects can be increased and the resistance rate can be reduced with effective management according to baseline factors and early on-treatment responses [3]. …”

Section: Introductionmentioning

confidence: 99%

Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B

et al. 2011

View full text Add to dashboard Cite

BackgroundAntiviral treatment with nucleoside analogs has been used for chronic hepatitis B (CHB). Each kind of nucleoside analog has its own characteristics and suitability for patients. Telbivudine (LdT, brand name: Sebivo, Beijing Novartis Pharma Ltd) is the newest nucleoside analog, with strong and rapid viral suppression. However, its resistance rate is relatively high during long-term application, due to low genetic barriers to resistance. So, it is necessary to increase the effect and reduce resistance with effective management, according to baseline factors and early on-treatment responses.ObjectivesTo reveal possible predictive factors of the effect of telbivudine (LdT) treatment on naïve HBeAg-positive chronic hepatitis B (CHB) patients to optimize treatment.Patients and MethodsA total 71 naïve chronic hepatitis B (CHB) patients who met the inclusion criteria were enrolled. All patients were treated with LdT 600 mg Qd for at least 52 weeks. Multiple logistic regression analyses were done to investigate the predictive values of baseline factors and responses at Week 24.ResultsThe reduction in hepatitis virus B (HBV) DNA level was 6.44 ± 2.38 lg copies/mL at Week 52 compared with baseline. The complete virus response (CVR), biochemical response (BR), serological response (SR), and drug resistance (DR) were 61.99%, 77.46%, 35.21%, and 8.45% respectively. By multiple regression analysis, baseline alanine aminotransferase (ALT) levels significantly affected CVR (P = 0.024, OR = 1.008), and baseline ALT and baseline HBV DNA levels were independent compact factors of SR (P = 0.012, OR = 1.007; P = 0.001, OR = 0.423). The differences in CVR, SR, and DR in patients with ALT > 120 Iu/mL compared with patients with ALT ≤ 120 Iu/mL were statistically significant. The differences in SR in patients with HBV DNA > 107 copies/mL compared with patients with HBV DNA ≤ 107 copies/mL were statistically significant. Additionally, CVR, BR, and SR were differed significantly between patients with HBV DNA lower than 300 copies/mL at Week 24 and patients with HBV DNA higher than 300 copies/mL (P = 0.000, P = 0.0016, and P = 0.000, respectively).ConclusionsThere were more responders among naïve HBeAg-positive chronic hepatitis B patients with lower HBV DNA levels (especially lower than 107 copies/mL) and higher ALT values (especially higher than 120 Iu/mL at baseline) to LdT treatment. Adjustments for treatment strategy should be considered if HBV DNA > 300 copies/mL at Week 24 is observed.

show abstract

“…At present, IFN-α and nucleoside analogs, including lamivudine, entecavir, telbivudine, emtricitabine, tenofovir, and adefovir, are used as treatment for chronic viral hepatitis 9,10 . Only subgroups of patients are treated with IFN-α is being eradicated for a long time.…”

Section: Discussionmentioning

confidence: 99%

Association of signal transducer and activator of transcription, interleukin-6, and interleukin-10 positivity with antiviral treatment in cirrhotic liver samples from patients with the hepatitis B or C virus

Tatlı¹,

Kırımlıoğlu²,

Yılmaz³

et al. 2018

Dicle Tıp Dergisi

View full text Add to dashboard Cite

Objective: Terminal liver disease due to viral hepatitis infections is an important health problem. This study aimed to compare the expression of members of the signal transducer and activator of transcription (STAT) family (STAT-1, -2, -3, -5a, and -5b) and interleukin (IL)-6 and IL-10 in hepatectomy material from patients who received antiviral treatment and underwent a liver transplantation due to terminal liver failure. Methods: The study consisted of 45 patients who underwent a liver transplantation due to chronic liver failure associated with viral hepatitis (hepatitis C virus [HCV] or hepatitis B virus [HBV]). The patients were divided into three groups according to the drug treatments they received prior to the liver transplantation: Group A: lamivudine, Group B: adefovir, and Group C: interferon or interferon + ribavirin. Results: In the study population, 9 (20%) patients were females and 36 (80%) were males. The mean age was 45.7 (29-69) years. STAT-2, -3, and IL-6 expression were significantly higher in hepatocytes in Group A (p<0.05). Conclusion: High STAT-3, high IL-6, and low STAT-1 expression were associated with optimum hepatocyte regeneration and liver metabolic function. In this regard, lamivudine was the most effective drug in the present study. Keywords: STAT family, IL-6/ IL-10, nucleoside analogs, interferon, liver transplantation Hepatit B ve Hepatit C Nedenli Sirotik Karaciğer Metaryalinde Sinyal transdüserleri ve transkripsiyon aktivatörleri, İnterlökin-6, İnterlökin-10 Pozitifliğinin Antiviral Tedavi ile İlişkisi ÖzGiriş: Viral hepatit infeksiyonlarına bağlı terminal dönem karaciğer hastalığı önemli bir sağlık sorunudur. Bu çalışmada antiviral tedavi almış terminal dönem karaciğer yetmezliği sebebiyle karaciğer nakli yapılan hepatektomi materyallerinde STAT-1,2,3,5,5a,5b, IL-6 ve IL-10 ekspresyonlarının karşılaştırılması amaçlandı.Yöntemler: viral hepatitler (HCV ve HBV)'e bağlı kronik karaciğer yetmezliği nedeni ile karaciğer transplantasyonu yapılan 45 olgu çalışmaya dâhil edildi. Çalışmamızda hastalar karaciğer transplantasyonu öncesi almış oldukları ilaç tedavilerine göre 3 gruba ayrıldı. Grup A: Lamuvidine, Grup B: Adefovir, Grup C: İnterferon veya interferon + ribavidin. Sonuçlar: Çalışma popülasyonunda 9 (%20) hasta kadındı ve 36 (%80) erkek idi. Yaş ortalaması 45.7 (29-69) idi. STAT-2, -3 ve IL-6 ekspresyonu Grup A'da hepatositlerde anlamlı olarak daha yüksekti (p <0.05).Sonuç: Yüksek STAT-3, yüksek IL-6 ve düşük STAT-1 ekspresyonu, optimumhepatositrejenerasyonu ve karaciğer metabolik fonksiyonu ile ilişkiliydi. Bu bağlamda, lamivudin, bu çalışmada en etkili ilaç olmuştur.

show abstract

A Review of Oral Antiretroviral Therapy for the Treatment of Chronic Hepatitis B

Abstract: Oral ARVs should continue to be used in the treatment of CHB; however, research is needed to define the optimal duration of therapy, evaluate the utility of combination therapy, and explore novel targets within the hepatitis B life cycle.

Cited by 9 publications

References 74 publications

Factors associated with the decrease in hepatitis B surface antigen titers following interferon therapy in patients with chronic hepatitis B: Is interferon and adefovir combination therapy effective?

Factors associated with the decrease in hepatitis B surface antigen titers following interferon therapy in patients with chronic hepatitis B: Is interferon and adefovir combination therapy effective?

Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B

Association of signal transducer and activator of transcription, interleukin-6, and interleukin-10 positivity with antiviral treatment in cirrhotic liver samples from patients with the hepatitis B or C virus

Contact Info

Product

Resources

About